Sort by
Keyphrases
Early Identification
100%
Early Treatment
100%
Cerebrotendinous Xanthomatosis
100%
Newborn Screening
100%
Dried Blood Spots
75%
Druze
25%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
25%
False Positive Rate
25%
MS-MS
25%
Flow Injection Analysis
25%
Israeli
12%
High Risk
12%
Jewish Population
12%
Metabolic
12%
Moroccan
12%
Bile Alcohol
12%
Genetic Variants
12%
Two-tier
12%
First-tier
12%
Gene Variants
12%
Glucuronide
12%
Leukodystrophy
12%
Prospective pilot Study
12%
Functional Cure
12%
Dried Samples
12%
Disease Marker
12%
Disease Prevalence
12%
Two-tier Test
12%
Tetrol
12%
CYP27A1 Gene
12%
Cholestane
12%
Alcohol-related Disorders
12%
Second-tier Test
12%
Medicine and Dentistry
Cerebrotendinous Xanthomatosis
100%
Newborn Screening
100%
Neonatal Infant
87%
Tandem Mass Spectrometry
50%
False Positive Result
25%
Liquid Chromatography-Mass Spectrometry
25%
Flow Injection Analysis
25%
Disease
12%
Prevalence
12%
Childbirth
12%
CYP27A1
12%
Bile
12%
Genetic Variability
12%
Leukodystrophy
12%
Disease Marker
12%
Cholestane Derivative
12%
Glucuronide
12%
Biochemistry, Genetics and Molecular Biology
Solution and Solubility
100%
Tandem Mass Spectrometry
100%
Newborn Screening
100%
Liquid Chromatography-Mass Spectrometry
50%
Genetic Divergence
25%
Cholestane
25%
Prevalence
25%
CYP27A1
25%
Glucuronide
25%